Leronlimab-Vyrologix, a humanized monoclonal antibody drug used to treat HIV patients, showed impressive results in improving the immune function of critically ill COVID-19 patients in the United States.
Developed by late-stage biotechnology company CytoDyn, Inc., Leronlimab-Vyrologix is a CCR5 (C-C chemokine receptor type 5) inhibiting drug that protects healthy T cells from viral infection. The CCR5 receptor, the National Center for Biotechnology Information says, plays a crucial role in modulating immune cell trafficking to sites of inflammation.
“Because of the drug’s ability to mitigate cytokine storm, which is common in COVID-19 fatalities, it has become the basis for its study as a potential COVID-19 treatment,” CytoDyn said in a statement.
CytoDyn’s recent treatment of patients under eIND (Emergency Investigational New Drug) with Leronlimab for COVID-19 infection has shown impressive results, with “hardly any” drug-related serious adverse events, as the drug reduced the plasma viral load and restored the immune function by the seventh day.
The company has already completed its Phase 2 clinical trial for COVID-19, a double-blinded, randomized clinical trial for mild-to-moderate COVID-19 patients in the U.S. The company has also recently announced that it has completed the enrollment of 394 patients in its Phase 2b/3 randomized clinical trial for the severe-to-critically ill COVID-19 population.
CytoDyn has appointed Chiral Pharma, a subsidiary of New Marketlink Pharmaceutical Corporation (NMPC) as its authorized partner for the distribution of Leronlimab-Vyrologix to the Philippines subject to registration approval of the Philippine Food and Drug Administration. Through the partnership, the companies are working to register Leronlimab under a licensed physician’s request for Compassionate Special Permit (CSP).
COMMENT DISCLAIMER: Reader comments posted on this Web site are not in any way endorsed by The Standard. Comments are views by thestandard.ph readers who exercise their right to free expression and they do not necessarily represent or reflect the position or viewpoint of thestandard.ph. While reserving this publication’s right to delete comments that are deemed offensive, indecent or inconsistent with The Standard editorial standards, The Standard may not be held liable for any false information posted by readers in this comments section.